← brief for 2026-10-14 · Slowing decline

Pharmacotherapy for MASLD/MASH: approved therapies, drug repurposing, and emerging mechanism-based candidates.

Paper No results yet Peer reviewed

Key takeaways

This is a review of drugs for fatty liver disease. It looks at new medicines and how they might help people with liver and kidney problems. It summarizes what is known so far. It does not report new test results from a single trial.

Who did this work

Syed-Abdul MM

Source

Paper · PubMed, the drug frontier · 2026 Oct 14
https://pubmed.ncbi.nlm.nih.gov/42870732/